These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18847418)

  • 1. [Clinical advances in vascular calcification].
    Fernández Giráldez ED
    Nefrologia; 2008; 28 Suppl 5():33-7. PubMed ID: 18847418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic kidney disease (CKD) and bone. Vascular calcification in CKD].
    Yokoyama K
    Clin Calcium; 2009 Apr; 19(4):552-8. PubMed ID: 19329835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data.
    Frazão JM; Adragão T
    Kidney Int Suppl; 2008 Dec; (111):S38-43. PubMed ID: 19034324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of secondary hyperparathyroidism].
    Cunningham J
    Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
    [No Abstract]   [Full Text] [Related]  

  • 7. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization.
    de Francisco AL; Piñera C; Palomar R; Arias M
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S281-5. PubMed ID: 17130275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Atheroma and vascular calcification in hemodialysis patients].
    Joki N; Tanaka Y
    Clin Calcium; 2010 Jul; 20(7):1061-6. PubMed ID: 20585185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
    Block GA; Spiegel DM; Ehrlich J; Mehta R; Lindbergh J; Dreisbach A; Raggi P
    Kidney Int; 2005 Oct; 68(4):1815-24. PubMed ID: 16164659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.
    Tokumoto M; Mizobuchi M; Finch JL; Nakamura H; Martin DR; Slatopolsky E
    Am J Nephrol; 2009; 29(6):582-91. PubMed ID: 19145073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.
    Block GA; Raggi P; Bellasi A; Kooienga L; Spiegel DM
    Kidney Int; 2007 Mar; 71(5):438-41. PubMed ID: 17200680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
    Qunibi W; Moustafa M; Muenz LR; He DY; Kessler PD; Diaz-Buxo JA; Budoff M;
    Am J Kidney Dis; 2008 Jun; 51(6):952-65. PubMed ID: 18423809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.
    Floege J; Raggi P; Block GA; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Chertow GM;
    Nephrol Dial Transplant; 2010 Jun; 25(6):1916-23. PubMed ID: 20110249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.